PT Asuransi Ramayana Tbk (ASRM) Stock Analysis 2026: Is This Indonesian Insurance Stock Undervalued?
Worldreview1989 - PT Asuransi Ramayana Tbk (IDX: ASRM) is a small-cap Indonesian insurance company that may attract value-oriented investors looking beyond the major names in Southeast Asia. The company has operated for decades, but its stock remains relatively small compared with Indonesia's largest financial institutions.
For U.S. investors, however, ASRM presents an unusual combination: a low price-to-book valuation, modest dividend, declining profitability, limited market capitalization, and potentially significant earnings volatility.
The key question is not simply whether ASRM is cheap.
The more important question is:
Is ASRM cheap because the market is overlooking a financially healthy insurer—or because its earnings power is deteriorating?
Based on the company's audited 2025 financial statements, 2026 developments, and the latest available market information, the answer is mixed.
ASRM Stock at a Glance
| Metric | ASRM |
|---|---|
| Company | PT Asuransi Ramayana Tbk |
| Ticker | ASRM |
| Exchange | Indonesia Stock Exchange |
| Industry | General Insurance |
| 2025 Insurance Service Revenue | Rp1.297 trillion |
| 2025 Net Income | Rp21.65 billion |
| 2025 EPS | ~Rp17 |
| 2025 Total Assets | Rp1.393 trillion |
| 2025 Total Equity | Rp707.78 billion |
| 2025 Net Cash From Operations | Rp5.15 billion |
| 2026 Dividend | Rp3/share |
| Approx. Market Price* | Rp282 |
| Approx. Market Capitalization* | Rp360 billion |
| Approx. PBV* | 0.5x |
| Approx. Trailing/2025 P/E | ~16–17x |
*Market data cited here reflects the latest available market information around late August 2026 and can change during trading.
The company's own investor-relations website provides audited 2025 financial statements and monthly 2026 financial reports.
What Does PT Asuransi Ramayana Do?
PT Asuransi Ramayana is an Indonesian general insurance company. Its business is primarily related to insurance protection rather than life insurance.
For an American investor, the easiest way to understand the business model is to compare it conceptually with a property-and-casualty insurer.
The company collects premiums, manages insurance risk, pays claims, purchases reinsurance protection and invests part of its available funds.
The investment thesis therefore depends on two major engines:
Insurance underwriting
Investment income
This distinction is extremely important when analyzing ASRM.
A general insurer can report strong premium growth but still produce weak shareholder returns if claims, acquisition expenses, reinsurance costs, and investment results deteriorate.
2025 Was a Difficult Year for ASRM
ASRM's audited 2025 financial statements show a significant deterioration in profitability.
Insurance service revenue declined from approximately Rp1.581 trillion in 2024 to Rp1.297 trillion in 2025, a decline of roughly 18%.
At the same time, insurance service expenses remained high at approximately Rp1.307 trillion.
The company did receive a substantial benefit from reinsurance contracts, producing approximately Rp163.9 billion of reinsurance contract income in 2025 compared with a negative amount in 2024.
As a result, net insurance service results were approximately Rp153.6 billion, compared with Rp157.5 billion in the previous year.
This is an important distinction.
Revenue declined sharply, but the deterioration in the core insurance-service result was much smaller because reinsurance contributed significantly.
The bigger problem was investment performance.
ASRM reported investment income of only about Rp16.3 billion in 2025, compared with approximately Rp61.3 billion in 2024.
After insurance finance expenses and reinsurance finance income, the company recorded a net investment result of approximately negative Rp58.4 billion, compared with negative Rp33.7 billion in 2024.
This significantly affected bottom-line profitability.
Net Profit Fell Sharply
ASRM generated approximately:
Rp48.2 billion of net income in 2024
Rp21.6 billion in 2025
That represents a decline of approximately 55%.
EPS consequently fell to around Rp17 per share.
For investors accustomed to U.S. stocks, this is one of the most important warning signals.
A low valuation multiple is not automatically attractive if earnings are falling rapidly.
A stock trading at 0.5x book value can still be expensive if its return on equity remains structurally weak.
Balance Sheet: The Stronger Part of the Story
The balance sheet provides a more positive picture.
At the end of 2025, ASRM reported:
Total assets: Rp1.393 trillion
Total liabilities: Rp631.6 billion
Total equity: Rp707.8 billion
Total assets declined from approximately Rp1.571 trillion in 2024, while liabilities fell substantially from approximately Rp864.1 billion.
Equity, however, increased from approximately Rp670.2 billion to Rp707.8 billion.
That creates an interesting valuation situation.
If ASRM trades around Rp282 per share, the market capitalization is only around Rp360 billion, while reported equity is above Rp707 billion.
In simple terms, the market is valuing the company at roughly half of book value.
That is potentially attractive from a value-investing perspective.
But investors should remember that book value is not the same thing as earning power.
Why Is ASRM Trading Below Book Value?
This is perhaps the most interesting question for value investors.
A price-to-book ratio below 1.0x can indicate:
investor pessimism,
weak profitability,
concerns about future earnings,
low liquidity,
limited institutional interest,
business-quality concerns,
or simply an undervalued asset.
ASRM currently appears to contain several of these characteristics.
Its reported 2025 ROE was only around 3%, based on net income relative to equity.
For a financial company, that is not particularly attractive.
A company generating only a few percentage points of return on equity has difficulty justifying a premium valuation.
Therefore, the market's discount to book value is understandable.
ASRM's Biggest Financial Problem: Low Return on Equity
One of the best ways for an American investor to evaluate a financial company is to ask:
How efficiently does management turn shareholder capital into profit?
ASRM's answer in 2025 was not impressive.
Using approximately Rp21.65 billion of net income and Rp707.8 billion of equity produces an ROE of roughly 3%.
That means the company generated only around Rp3 of annual profit for every Rp100 of shareholder equity.
This is significantly below what many investors would expect from a high-quality financial business.
The valuation therefore requires improvement in profitability.
If ASRM can eventually return to higher earnings while maintaining its current equity base, the stock could potentially re-rate.
If earnings remain around Rp20–25 billion annually, the current discount to book value may be justified.
Cash Flow Improved Dramatically
One of the positive developments in 2025 was operating cash flow.
ASRM generated approximately:
Rp5.15 billion of net operating cash flow in 2025
compared with:
negative Rp218.17 billion in 2024.
The improvement was substantial.
The company's cash-flow statement shows approximately Rp906.8 billion of premium receipts in 2025 and around Rp696.7 billion of claim payments.
It also paid approximately Rp272.5 billion in reinsurance premiums and Rp151.1 billion in brokerage commissions and reductions.
For insurance investors, cash flow deserves close attention because accounting earnings can be affected by changes in insurance-contract measurement.
The improvement from deeply negative operating cash flow to positive cash generation is therefore encouraging.
However, Rp5 billion of operating cash flow on more than Rp1.2 trillion of insurance revenue is still relatively modest.
PSAK 117 Makes the Numbers More Difficult to Compare
One issue U.S. investors should understand is the implementation of PSAK 117, Indonesia's insurance-contract accounting standard based on IFRS 17 principles.
ASRM adopted PSAK 117 beginning January 1, 2025.
The company's independent auditor identified the valuation of insurance contract liabilities and the first-time adoption of PSAK 117 as a key audit matter.
The audited statements show insurance contract liabilities of approximately Rp326.1 billion at December 31, 2025. The valuation involves significant assumptions regarding future claims, risk exposure, fulfilment cash flows and contractual service margins.
The auditor stated that the methodologies and assumptions used by management were adequate based on the audit procedures performed.
For investors, however, this means year-to-year comparisons should be interpreted carefully.
The accounting framework has changed, and insurance profitability is increasingly influenced by actuarial assumptions and contract-service accounting.
ASRM's 2026 Performance: Another Warning Sign
The first half of 2026 deserves attention.
According to financial reporting for the second quarter, ASRM's 6-month 2026 net profit was approximately Rp10.3 billion, compared with approximately Rp26.5 billion in the comparable 2025 period.
That represents a decline of more than 60%.
This suggests that the weakness in profitability did not disappear after the difficult 2025 financial year.
Revenue was also substantially lower in the six-month figures reported by the market-data source.
Therefore, investors should be careful about assuming that ASRM's low PBV automatically represents a near-term turnaround opportunity.
The earnings trend is currently the biggest obstacle to a bullish thesis.
Dividend Analysis
ASRM is not primarily a high-dividend stock.
For the 2025 financial year, shareholders approved a cash dividend of:
Rp3 per share
with total cash dividends of approximately Rp3.834 billion.
That represented approximately 17.17% of the relevant profit allocation.
The remaining approximately Rp17.813 billion was allocated to general reserves.
At a share price around Rp282, a Rp3 dividend implies a historical dividend yield of approximately:
1.06%
That is modest.
For a U.S. income investor, ASRM therefore should not be viewed as an Indonesian equivalent of a high-yield insurance stock.
The more interesting thesis is potential capital appreciation if earnings recover and the PBV discount narrows.
A Simple Valuation Exercise
Assume ASRM trades around Rp282.
The 2025 book value per share is approximately:
Rp554
That means:
PBV ≈ 0.51x
This looks inexpensive.
But let's examine three scenarios.
Bear Case
Assume earnings remain weak and ROE stays around 3%.
The market may continue valuing ASRM at approximately 0.4–0.6x book.
Under this scenario, the stock could remain trapped in a low valuation range.
Investment view: Neutral to bearish.
Base Case
Assume earnings stabilize and gradually recover toward Rp30–40 billion annually.
If investors become more confident about profitability, the market could potentially assign a PBV closer to 0.6–0.8x.
This would create meaningful upside from approximately Rp282.
Investment view: Moderately bullish.
Bull Case
Assume underwriting improves, investment income normalizes and annual earnings recover substantially.
If ROE moves meaningfully higher and investors become willing to value the company closer to book value, the theoretical share price could move toward the Rp500 area.
However, this should be considered a scenario rather than a price target.
There is no guarantee that ASRM will achieve that earnings recovery.
What American Investors May Like About ASRM
From the perspective of a U.S.-based value investor researching Indonesian equities, several characteristics are attractive.
1. Very low price-to-book ratio
A valuation around 0.5x book provides a substantial asset-value discount.
2. Established operating history
ASRM is not a newly created insurance startup.
The company has decades of operating history.
3. Improving operating cash flow
The move from negative operating cash flow in 2024 to positive operating cash flow in 2025 is encouraging.
4. Lower liabilities
Total liabilities fell significantly during 2025.
5. Dividend distribution
Although small, the company continues to return some capital to shareholders.
What American Investors May Dislike
The risks are equally important.
1. Earnings deterioration
Net profit fell by roughly 55% in 2025.
2. Weak ROE
A roughly 3% ROE is not compelling for a financial company.
3. Weak investment results
The net investment result remained negative in 2025.
4. Small market capitalization
ASRM's market value is only several hundred billion rupiah.
For U.S. institutional investors, this creates a significant liquidity and position-sizing problem.
5. Thin trading liquidity
Small Indonesian stocks can experience larger spreads and greater price volatility than large-cap U.S. equities.
6. Currency risk
An American investor buying ASRM is exposed to both the stock and the Indonesian rupiah.
Even if ASRM rises in rupiah terms, a weaker rupiah can reduce the investment return measured in U.S. dollars.
7. Insurance accounting complexity
PSAK 117 makes the interpretation of insurance liabilities, service results and profitability more complicated.
A Reader-Oriented View: Would a U.S. Investor Buy ASRM?
An American investor evaluating ASRM would probably ask the same questions used when analyzing a small U.S. insurance company:
Is the book value real?
Yes, the company reports substantial equity and assets.
Is the company profitable?
Yes, but profitability deteriorated sharply.
Is profitability improving?
The latest 2026 results do not yet provide convincing evidence of a sustained recovery.
Is the stock cheap?
On a price-to-book basis, yes.
Is it cheap for a reason?
Probably.
The combination of weak ROE, declining earnings and small capitalization helps explain the discount.
Is there a catalyst?
Potential catalysts include a recovery in insurance revenue, improved underwriting margins, stronger investment income, better operating efficiency and a sustained improvement in ROE.
ASRM vs. a Typical U.S. Insurance Investment
The difference between ASRM and a large U.S. insurer is important.
A large American insurer can benefit from:
massive investment portfolios,
diversified insurance lines,
large distribution networks,
greater liquidity,
stronger analyst coverage,
institutional ownership,
and economies of scale.
ASRM is much smaller.
Therefore, investors should not value it simply by comparing its P/B ratio with large global insurers.
A better comparison would be with small and mid-sized emerging-market general insurers.
The appropriate discount rate should also reflect:
Indonesian market risk,
currency risk,
liquidity risk,
company size,
earnings volatility,
and insurance-sector regulatory risk.
The Most Important Metric to Watch in 2026–2027
Investors should not focus only on revenue.
The most important metric may be:
ROE
If ASRM can increase ROE from roughly 3% toward:
5%,
7%,
or eventually 10%+,
the investment thesis becomes much more interesting.
Why?
Because a low-PBV stock can remain cheap indefinitely when its return on equity is poor.
But when profitability improves, investors often become willing to pay a higher multiple of book value.
That creates the possibility of a valuation re-rating.
Five Things Investors Should Monitor
Before buying ASRM, investors should monitor these five indicators every quarter.
1. Insurance service revenue
Is the business shrinking or recovering?
2. Net insurance service result
This is more important than simply looking at premium growth.
3. Investment result
The 2025 deterioration demonstrates how investment performance can materially affect profitability.
4. ROE
A sustained improvement would strengthen the valuation case.
5. Solvency and capital adequacy
For an insurance company, financial strength matters just as much as earnings.
OJK's reporting framework requires insurance companies to provide standardized periodic financial and solvency information.
Final Verdict: Is ASRM Stock a Buy?
ASRM is interesting, but it is not an obvious buy based solely on its low PBV.
The stock appears inexpensive relative to reported book value, with a valuation around half of book value at recent prices.
That is the primary attraction.
However, the company's 55% decline in 2025 net income, weak ROE and continuing profit pressure in 2026 make the stock more appropriately classified as a deep-value/turnaround situation rather than a high-quality compounder.
My investor classification
| Factor | Assessment |
|---|---|
| Valuation | 🟢 Attractive |
| Price-to-book | 🟢 Very attractive |
| Profitability | 🔴 Weak |
| Earnings growth | 🔴 Weak |
| Balance sheet | 🟢 Reasonable |
| Operating cash flow | 🟡 Improving |
| Dividend | 🟡 Low |
| Liquidity | 🔴 High risk |
| Business maturity | 🟢 Established |
| Turnaround potential | 🟡 Interesting |
| Overall | 🟡 Speculative Value |
For a conservative U.S. investor, ASRM probably does not deserve a large portfolio allocation.
For a sophisticated emerging-market value investor, however, the stock is worth monitoring because the discount to book value is substantial.
The investment case becomes considerably stronger if ASRM can demonstrate three consecutive improvements:
higher insurance revenue + stronger underwriting results + materially higher ROE.
Until that happens, the low valuation should be viewed as a margin of safety—not proof that the stock is undervalued.
Bottom Line
PT Asuransi Ramayana Tbk (IDX: ASRM) is a small Indonesian insurance stock trading at a substantial discount to book value, but its weak earnings performance prevents it from being an obvious bargain.
The 2025 financial statements show:
approximately Rp1.30 trillion in insurance service revenue,
approximately Rp21.6 billion in net profit,
approximately Rp707.8 billion in equity,
approximately Rp1.39 trillion in assets,
and approximately Rp5.15 billion of positive operating cash flow.
The company also approved a Rp3-per-share dividend for 2025.
The valuation looks cheap.
The earnings trend does not.
That tension is what makes ASRM an interesting stock to watch in 2026—not necessarily a stock to buy blindly.
Investment stance: WATCH / SPECULATIVE VALUE, pending evidence of a sustainable earnings and ROE recovery.
This article is for educational purposes only and is not personalized investment advice. Indonesian equities, particularly small-cap stocks, can involve significant liquidity, currency and volatility risks.
About the Author
David Mulyana is the founder and editor of WorldReview1989, an independent publication dedicated to finance, investing, insurance, business, technology, and digital marketing.
He researches and writes in-depth articles that help readers understand complex financial topics through clear explanations, practical insights, and data-driven analysis. His editorial focus includes stock market investing, cryptocurrencies, banking, personal finance, business insurance, real estate, startup strategies, and emerging technology trends.
Every article published on WorldReview1989 is created with a commitment to accuracy, transparency, and reader value. Content is reviewed regularly to reflect the latest market developments, industry updates, and publicly available information from trusted sources.
Editorial Principles
- Accuracy before speed
- Independent and unbiased analysis
- Clear, easy-to-understand explanations
- Information supported by reputable public sources
- Regular updates to maintain content relevance
Areas of Expertise
- Personal Finance
- Investing & Stock Market
- Cryptocurrency & Blockchain
- Insurance
- Banking
- Real Estate
- Business & Entrepreneurship
- Digital Marketing
- Financial Technology (FinTech)
About WorldReview1989
WorldReview1989 provides educational content for readers seeking reliable information about finance, investment opportunities, insurance, business strategies, and technology. The website aims to simplify complex financial concepts and empower readers to make informed decisions.
Disclaimer: The information published on WorldReview1989 is for educational and informational purposes only. It should not be considered financial, legal, tax, or investment advice. Readers should consult qualified professionals before making financial decisions.
David Mulyana writes about stocks, financial markets, investment strategies, insurance and emerging-market opportunities, with a focus on helping readers understand financial data and investment risks
Join Facebook Group